This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Edward Li, PharmD, MPH, BCOP
University of New England College of Pharmacy

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.



 

Download Transcript

 
 

Download Slides


 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

JADPRO CE Logo APSHO Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.